13D Filing: Phase4 Partners Ltd and Albireo Pharma Inc. (ALBO)

This Amendment No. 1 (“Amendment No. 1”) amends the Statement on Schedule 13D first filed with the Securities and Exchange Commission on November 3, 2016, (as amended, the “Schedule 13D”), and is filed by the Reporting Persons with respect to the common stock, par value $0.01 per share (the “Common Stock”), of Albireo Pharma, Inc. (the “Issuer”). Capitalized terms used herein but not defined

Item 5.

Interest in Securities of the Issuer.

(a)-(b):

Number of shares of Common Stock beneficially owned:

Phase4 Partners		1,065,447 shares
Phase4 III		1,065,447 shares
Phase4 GPLP		1,065,447 shares
Phase4 GP		1,065,447 shares
Dr. Alastair McKinnon		1,065,447 shares
Denise Scots-Knight, Ph.D.		1,065,447 shares
Charles Sermon		1,065,447 shares

Percent of class:

Phase4 Partners Limited		9.56%
Phase4 Ventures III LP		9.56%
Phase4 Ventures III GP LP		9.56%
Phase4 Ventures III General Partner Limited		9.56%
Dr. Alastair McKinnon		9.56%
Dr. Denise Scots-Knight		9.56%
Charles Sermon		9.56%

(The percentage ownership was calculated based on 11,148,285 shares of common stock outstanding as of the completion of the offering disclosed in the Prospectus Supplement to the Registration Statement on Form S-3 (File No. 333-220958) filed by the Issuer with the Securities and Exchange Commission on January 25, 2018, and the disclosure by the Issuer of the successful completion of this offering in a press release dated January 29, 2018.)